Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An update on the discovery and development of reversible covalent inhibitors
Faridoon Faridoon, Raymond Ng, Guiping Zhang, et al.
Medicinal Chemistry Research (2023) Vol. 32, Iss. 6, pp. 1039-1062
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives
Jiahao Li, Gong Chen, Haiting Zhou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5489-5489
Open Access | Times Cited: 21
Michael Acceptors as Anti-Cancer Compounds: Coincidence or Causality?
Celia María Curieses Andrés, José Manuel Pérez de la Lastra, Elena Bustamante Munguira, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6099-6099
Open Access | Times Cited: 13
Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on SNAr Electrophiles
Moritz Schwarz, Maksym Kurkunov, Florian Wittlinger, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6549-6569
Closed Access | Times Cited: 9
Covalent hits and where to find them
Simon C. C. Lucas, J. Henry Blackwell, Sarah H. Hewitt, et al.
SLAS DISCOVERY (2024) Vol. 29, Iss. 3, pp. 100142-100142
Open Access | Times Cited: 7
Reversible Covalent Inhibition─Desired Covalent Adduct Formation by Mass Action
Disha Patel, Zil E Huma, Dustin Duncan
ACS Chemical Biology (2024) Vol. 19, Iss. 4, pp. 824-838
Open Access | Times Cited: 7
AI-driven covalent drug design strategies targeting main protease (m pro ) against SARS-CoV-2: structural insights and molecular mechanisms
Mohammad Hossein Haghir Ebrahim Abadi, Abdulrahman Ghasemlou, Fatemeh Bayani, et al.
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-29
Closed Access | Times Cited: 4
Virtual screening of targeted acrylamide warheads for identification of covalent inhibitors of Cryptopain, a cysteine protease of Cryptosporidium parvum
Misgana Mengistu Asmare, Ajit Kumar Dhal, Rajani Kanta Mahapatra, et al.
Journal of Biomolecular Structure and Dynamics (2025), pp. 1-16
Closed Access
Key advances in the development of reversible covalent inhibitors
Faridoon Faridoon, Jiyue Zheng, Guiping Zhang, et al.
Future Medicinal Chemistry (2025), pp. 1-4
Closed Access
Synthesis, screening and validation of cysteine-reactive fragments as chikungunya virus protease inhibitors
Junming He, Henry Illingworth, Sven Ullrich, et al.
Bioorganic & Medicinal Chemistry Letters (2025), pp. 130176-130176
Open Access
Targeting Cysteine Protease B to Discover Antileishmanial Drugs: Directions and Advances
Esteban F. Rios, Sonaly Lima Albino, Ricardo Olímpio de Moura, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117500-117500
Closed Access
The unprecedented Paxlovid journey from milligrams to millions of patient doses during the Covid-19 pandemic
Weili Yu, Mahesh K. Krishnan, Matt Weekly, et al.
Communications Medicine (2025) Vol. 5, Iss. 1
Open Access
Unified Deep Learning of Molecular and Protein Language Representations with T5ProtChem
Thomas J. Kelly, Song Xia, Jieyu Lü, et al.
Journal of Chemical Information and Modeling (2025)
Closed Access
Structure based design, synthesis and identification of novel covalent reversible dual TLR2/TLR9 small molecule antagonists
Srinivasa Reddy Natala, Agata Habas, Emily M. Stocking, et al.
Bioorganic & Medicinal Chemistry Letters (2025), pp. 130259-130259
Closed Access
Achieving High Affinity for a Bacterial Lectin with Reversible Covalent Ligands
Giulia Antonini, Anna Bernardi, Émilie Gillon, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 21, pp. 19546-19560
Closed Access | Times Cited: 3
Computational analysis of the interactions between Ebselen and derivatives with the active site of the main protease from SARS-CoV-2
Guilherme Schmitt Rieder, Pablo A. Nogara, Folorunsho Bright Omage, et al.
Computational Biology and Chemistry (2023) Vol. 107, pp. 107956-107956
Closed Access | Times Cited: 8
Advanced technologies for screening and identifying covalent inhibitors
Yaolin Guo, Shuai Wen, Aiping Tong, et al.
TrAC Trends in Analytical Chemistry (2024) Vol. 178, pp. 117833-117833
Closed Access | Times Cited: 2
Structural review of SARS-CoV-2 antiviral targets
Wen Cui, Yinkai Duan, Gao Yan, et al.
Structure (2024) Vol. 32, Iss. 9, pp. 1301-1321
Closed Access | Times Cited: 2
Enzyme Inhibitors as Multifaceted Tools in Medicine and Agriculture
Sonia Del Prete, Mario Pagano
Molecules (2024) Vol. 29, Iss. 18, pp. 4314-4314
Open Access | Times Cited: 2
Covalent-reversible peptide-based protease inhibitors. Design, synthesis, and clinical success stories
Anthony Feral, Anthony R. Martin, Alexandre Desfoux, et al.
Amino Acids (2023) Vol. 55, Iss. 12, pp. 1775-1800
Closed Access | Times Cited: 5
Development of Highly Potent and Selective FGFR4 Inhibitors Based on SNAr Electrophiles
Moritz Schwarz, Maksym Kurkunov, Florian Wittlinger, et al.
(2024)
Open Access | Times Cited: 1
Isotope-labeled click-free probes to identify protein targets of lysine-targeting covalent reversible molecules
Xingyu Ma, Yixin Chen, Zi Ye, et al.
Chinese Chemical Letters (2024), pp. 110203-110203
Closed Access | Times Cited: 1
Chemoselective Reagents for the Traceless Bioreversible Modification of Native Proteins
Yana Petri, Forrest G. FitzGerald, Ronald T. Raines
Bioconjugate Chemistry (2024) Vol. 35, Iss. 9, pp. 1300-1308
Open Access | Times Cited: 1
Trends in covalent drug discovery: a 2020-23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in fda-approved drugs
Jan Felix Scholtes, Cristóbal Alhambra, Philip A. Carpino
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 10, pp. 843-861
Closed Access | Times Cited: 1
Towards imaging the immune state of cancer by PET: Targeting legumain with 11C-labeled P1-Asn peptidomimetics carrying a cyano-warhead
Severin Lustenberger, Claudia A. Castro Jaramillo, Lena A Bärtschi, et al.
Nuclear Medicine and Biology (2024) Vol. 138-139, pp. 108951-108951
Open Access | Times Cited: 1
Slow-Binding and Covalent HDAC Inhibition: A New Paradigm?
Yasir S. Raouf, Carlos Moreno–Yruela
JACS Au (2024) Vol. 4, Iss. 11, pp. 4148-4161
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top